The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management is pivoting from a generalist sales model to a specialist, scientist-led engagement approach to better capture market demand for complex modeling services.

The divestiture of the regulatory and medical writing business was a strategic move to sharpen focus on the core software-services flywheel and improve financial predictability.

Software revenue now constitutes 53% of the business, up from 40% two years ago, reflecting a deliberate shift toward a more scalable, high-margin product mix.

A 5% global workforce reduction was executed to eliminate stranded costs from the recent divestiture and redirect capital toward high-growth innovation and AI initiatives.

Performance in the quarter was bolstered by global regulatory shifts, such as the ICH M15 standard, which harmonizes model-informed drug development across the U.S. and Europe.

The company is leveraging its 25-year proprietary dataset to create an 'accountability layer' for AI, distinguishing its specialized tools from generic AI models in regulated environments.

Full-year revenue guidance of 0% to 4% is reaffirmed, with software expected to perform at or above the high end while services may lag at or below the low end.

A 27% year-over-year increase in the pipeline exiting Q2 is expected to translate into improved revenue growth during the second half of 2026.

Management anticipates that the $13 million in run-rate savings from operational excellence initiatives will fully materialize in future periods to support margin expansion.

The transition from desktop to cloud-based software is providing greater visibility into future revenue streams and driving momentum for the Phoenix platform.

Strategic focus is shifting toward international expansion in Europe and Asia, specifically targeting outsized growth potential in China, Japan, and the Middle East.

The divestiture of the regulatory business resulted in 'stranded costs' where shared infrastructure remains despite the loss of associated revenue, impacting near-term margins.

Adjusted EBITDA margin guidance was revised to 29% to 31% solely to reflect the new business composition following the divestiture, not underlying performance issues.

A new $50 million share repurchase program was authorized following the completion of a previous $100 million program, signaling confidence in the current valuation.

The company reported a net loss from continuing operations of $6.1 million, primarily due to the absence of a prior-year contingent consideration adjustment and currency headwinds.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

The partnership enables NVIDIA agents to interface with Certara software and accelerates high-throughput data processing for earlier drug discovery indicators.

Management declined to provide specific timelines for financial impact but views it as a modernization of how their software is consumed by clients.

The previous generalist sales model was identified as a mistake; the company is now hiring PhD-led sales teams to drive scientific engagement.

While pipeline creation is up nearly 29%, management is maintaining a cautious outlook on the 'rate and pace' at which this converts to burned revenue.

Certara's performance is not currently dependent on biotech funding cycles because their work typically begins as discovery translates into development.

Management emphasized that current growth is an 'execution story' focused on capturing existing market share rather than waiting for macro improvements.